SARS COV-2 Assessment and Treatment Guidelines
The global fight against COVID-19 continues to evolve, with new research and clinical evidence shaping updated treatment guidelines. Here, we provide an overview of the latest recommendations for managing COVID-19, focusing on key advancements in therapies, preventive strategies, and patient management. Assessment of Clinical severity of COVID 19 to target treatments Mild to moderate COVID 19 spO2 > 94% on room air and not needing supplemental oxygen but with risk factors for progression to severe disease, hospitalization or death Severe COVID -19 Sp02 < 94 % on room air or needing low flow supplemental oxygen Critical COVID -19 Needing high flow oxygen or NIV Critical COVID-19 Needing mechanical ventilation or ECMO Risk factors: Age > 60 years, BMI > 25 years, hypertension, cardiovascular disease, Chronic lung disease, chronic kidney disease, immunocompromised states Treatment Mild to moderate COVID-19 with risk factors for progression to severe disease, hospitalization or death Nirmatrelvir Plus ritonavir Must be started within 5 days of onset of symptoms Molnupiravir Must be started within 5 days of onset of symptoms Remdesivir Give as IV infusions for 3 days in health care facility Severe to critical COVID 19 requiring oxygen administration in any form 1. Dexamethasone IV 2. Remdesivir 3. IL-6 receptor blocking agent like Tocilizumab 4. JAK stat signalling pathway block like Baricitnib or Tofacitnib 5. Enoxaparin in elevated D dimer levels with documented thromboembolism. Prevention of DVT with enoxaparin for all hospitalized patients Post-Exposure Prophylaxis (PEP) Evusheld (tixagevimab/cilgavimab) remains an option where effective against circulating variants, pending local guidelines. Step up Oxygen Therapy Non-invasive ventilation as the initial strategy for hypoxic patients High-flow nasal oxygen Early intubation for patients with refractory hypoxia or progressive respiratory failure Anticoagulation: -Prophylactic-dose anticoagulation for all hospitalized COVID-19 patients unless contraindicated. -Therapeutic-dose anticoagulation for selected cases with documented thrombosis or high D-dimer levels.

